<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-B3LOSNLH</identifier><date>2022</date><creator>Berlec, Aleš</creator><relation>documents/doc/B/URN_NBN_SI_doc-B3LOSNLH_001.pdf</relation><relation>documents/doc/B/URN_NBN_SI_doc-B3LOSNLH_001.txt</relation><format format_type="issue">2</format><format format_type="volume">73</format><format format_type="type">article</format><format format_type="extent">str. 89-94</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">108023555</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-B3LOSNLH</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">nusinersen</subject><subject language_type_id="slv">onasemnogen abeparvovek</subject><subject language_type_id="slv">risdiplam</subject><subject language_type_id="eng">spinal muscular atrophy</subject><subject language_type_id="slv">spinalna mišična atrofija</subject><subject language_type_id="eng">treatment</subject><subject language_type_id="slv">zdravljenje</subject><title>new options for the treatment of spinal muscular atrophy</title><title>Nove možnosti zdravljenja spinalne mišične atrofije</title></Record>